By Kat Greene ( April 3, 2017, 5:10 PM EDT) -- AbbVie Inc. is looking to invalidate a suite of Novartis patents, arguing Friday in California that its Swiss rival is collecting licensing fees on the genetic makeup of the Hepatitis C virus, despite the U.S. Supreme Court's Alice ruling expressly stating nature itself can't be patented....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.